Candriam S.C.A. Relmada Therapeutics, Inc. Transaction History

Candriam S.C.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$2.17 - $35.84 $178,849 - $2.95 Million	-82,419 Reduced 47.2%	92,186 $321,000
Q3 2022 Nov 10, 2022	BUY	$18.3 - $37.02 $593,267 - $1.2 Million	32,419 Added 22.8%	174,605 $6.46 Million
Q2 2022 Aug 03, 2022	BUY	$16.5 - $30.34 $107,415 - $197,513	6,510 Added 4.8%	142,186 $2.7 Million
Q1 2022 May 13, 2022	BUY	$16.72 - $26.99 $2.27 Million - $3.66 Million	135,676 New	135,676 $3.66 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $11.7M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.